Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 1/20 | 0.75 |
| ▸ | NPY2R | P49146 | 13/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | PRLHR | P49683 | 3/20 | 0.61 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.59 |
| ▸ | KCNMB4 | Q86W47 | 1/20 | 0.59 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.59 |
| ▸ | MC4R | P32245 | 1/20 | 0.59 |
| ▸ | MC1R | Q01726 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL63125 | 0.87 | INSR (0.98) | INSRNPY2RRXFP1KCNMA1KCNMB4 | |
| SCHEMBL15669703 | 0.86 | INSR (0.95) | INSRNPY2RRXFP1KCNMA1KCNMB4 | |
| SCHEMBL14840198 | 0.85 | INSR (0.93) | INSRNPY2RRXFP1KCNMA1KCNMB4 | |
| Calcitonin Human SCHEMBL29381354 | 0.82 | INSR (0.63) | INSRNPY2RPRLHRNPFFR2 | |
| Calcitonin Salmon SCHEMBL29392873 | 0.81 | INSR (0.64) | INSRNPY2R | |
| Calcitonin Salmon SCHEMBL269785 | 0.81 | INSR (0.64) | INSRNPY2R | |
| Procalcitonin SCHEMBL29357049 | 0.81 | INSR (0.62) | INSRNPY2RPRLHR | |
| SCHEMBL30888738 | 0.81 | NPY2R (0.63) | INSRNPY2R | |
| Insulin Detemir SCHEMBL29350489 | 0.81 | INSR (0.82) | INSRNPY2RRXFP1KCNMA1KCNMB4 | |
| SCHEMBL29385832 | 0.80 | MC4R (0.72) | INSRNPY2RRXFP1PRLHRKCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9102 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4398874-A1 | INJECTABLE HIGH CONCENTRATION PHARMACEUTICAL FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF | Xeris Pharmaceuticals, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| CN-118317807-A | Controlled wash recovery using tissue plasminogen activator (tPA) | 阿比奥梅德公司 | 2024-07-09 | — | — | CN | claimed |
| US-12029755-B2 | Carbon monoxide-based therapies and implantable devices for the treatment of vascular disease | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-07-09 | — | — | US | claimed |
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | ACERTA PHARMA BV (NL) | 2024-07-04 | — | — | US | claimed |
| CN-118251491-A | CRISPR/Cas related methods and compositions for knockout of C5 | 瑞泽恩制药公司 | 2024-06-25 | — | — | CN | claimed |
| US-20240189495-A1 | METHODS OF PREPARING AN EXTRACORPOREAL CIRCUIT FOR ANTICOAGULATION | LOWELL THERAPEUTICS, LLC | 2024-06-13 | — | — | US | claimed |
| US-20240180904-A1 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2024-06-06 | — | — | US | claimed |
| CN-118103030-A | Injectable high concentration pharmaceutical formulations and methods of making and using the same | XERIS药物公司 | 2024-05-28 | — | — | CN | claimed |
| EP-4362959-A1 | COMPOSITION AND PROCESS FOR AN INFILTRATION AND TRANSPORT MEDIUM FOR ADIPOSE TISSUE CELLS | Universiteit Gent (BE) | 2024-05-08 | — | — | EP | claimed |
| US-20240139027-A1 | DIAGNOSTIC METHODS AND APPARATUS | FORSIGHT VISION4, INC. | 2024-05-02 | — | — | US | claimed |
| WO-2002049650-A2 | PHARMACEUTICAL FORMULATION CONTAINING THIENOPYRIMIDINES AND ANTITHROMBOTICS, CALCIUM ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | claimed |
| WO-2002049649-A2 | PHARMACEUTICAL FORMULATION CONTAINING THIENOPYRIMIDINES AND ANTITHROMBOTICS, CALCIUM ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES (2) | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | claimed |
| WO-2002049651-A1 | PHARMACEUTICAL FORMULATION CONTAINING PYRAZOLO[4,3-D]PYRIMIDINES AND ANTITHROMBOTIC AGENTS, CALCIUM-ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | claimed |
| WO-2002043806-A2 | IN VIVO DELIVERY METHODS AND COMPOSITIONS | RHEOLOGICS, INC (US) | 2002-06-06 | — | — | WO | claimed |
| US-20020061835-A1 | Administering a drug to a human which is pharmaceutically effective to regulate at least one of the blood parameters used to adjust distribution of the drug through the bloodstream | RHEOLOGICS, INC. | 2002-05-23 | — | — | US | claimed |
| US-20020032149-A1 | Monitoring blood flow parameter of bloodstream, administering substance to organism such that an amount of substance enters bloodstream; distributing portion of amount ofsubstance target within organism | RHEOLOGICS, INC. | 2002-03-14 | — | — | US | claimed |
| WO-2002019935-A1 | METHOD AND SYSTEM FOR ANTICOAGULANT DOSE REVISION | THE RXFILES CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| US-20010044584-A1 | In vivo delivery methods and compositions | RHEOLOGICS, INC. | 2001-11-22 | — | — | US | claimed |
| US-20010038862-A1 | Topical and transdermal administration of peptidyl durgs using hydroxide releasing agents as permeation enhancers | TECHNOLOGY RECOVERY SYSTEMS, LLC | 2001-11-08 | — | — | US | claimed |
| CN-1088836-A | Lepirudin 023 ludon and complex thereof are used for preparation prevention and treatment thrombotic disease medicine | BIOLOGY INST CHINESE ACADEMY O (CN) | 1994-07-06 | — | — | CN | claimed |